AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Donald Trump’s $1.4 trillion tariff threats scramble business plans, US companies form task-forces to tackle impact
Companies in the US, including Novo Nordisk, Boeing and Shein, are forming task forces to address the impact of Donald ...
Pulmonology Advisor1d
Novo Nordisk Provides Direct-to-Patient Delivery Option for Wegovy
Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.
Stifel Nicolaus Downgrades Novo Nordisk A/S (NYSE:NVO) to Hold
Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...
Monthly Prescribing Reference9d
Novo Nordisk Provides Direct-to-Patient Delivery Option for Wegovy
US Operations and Global Business Development and President of Novo Nordisk Inc. “With NovoCare Pharmacy, patients and prescribers alike have another option that provides convenient access to ...
Novo to Sell Weight-Loss Drug Wegovy Directly to Patients
Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US ...
Business Wire10d
Gensaic Announces Collaboration with Novo Nordisk to Unlock Next Generation Precision Therapies
--(BUSINESS WIRE)--Gensaic, Inc. (Gensaic), a biotechnology ... For more information, please visit gensaic.com and follow us on LinkedIn. About Novo Nordisk Novo Nordisk is a leading global ...
Pharmabiz17d
US FDA declares Wegovy & Ozempic shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses
US operations and global business development and president of Novo Nordisk Inc. "Patient safety remains our top priority and, in line with our purpose to improve lives and health, we continue to ...
CNN20d
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ... president of Novo Nordisk Inc., said in a statement Friday.